U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07441226) titled 'Umbilical Cord Mesenchymal Stem Cells as Adjuvant Therapy in Group E COPD Patients' on Feb. 01.
Brief Summary: This study aims to evaluate the efficacy and safety of allogeneic human UC-MSC to treat stage E Chronic Obstructive Pulmonary Disease (COPD).
All participants in this study already receive standard treatment for COPD, which includes triple inhaled medications with LABA, LAMA and ICS.
We hypothesize that UC-MSCs will improve COPD management. UC-MSCs are prepared in a certified laboratory and given intravenously. For 12 months from day 0, all patients will be observed for comprehensive safety evaluation, pulmonary function ...